# SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

> **NCT02819856** · PHASE2 · COMPLETED · sponsor: **Sound Pharmaceuticals, Incorporated** · enrollment: 40 (actual)

## Conditions studied

- Ototoxicity

## Interventions

- **DRUG:** Placebo
- **DRUG:** SPI-1005 Ebselen 200mg Capsule x1
- **DRUG:** SPI-1005 Ebselen 200mg Capsule x2
- **DRUG:** SPI-1005 Ebselen 200mg Capsule x3

## Key facts

- **NCT ID:** NCT02819856
- **Lead sponsor:** Sound Pharmaceuticals, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-21
- **Primary completion:** 2023-04-07
- **Final completion:** 2023-04-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819856, "SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02819856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*